Rituximab with pentostatin or cladribine: An effective combination treatment for hairy cell leukemia after disease recurrence

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 2, 2011, Pages 75-78

  Else, Monica ^a   Dearden, Claire E ^a   Matutes, Estella ^a   Forconi, Francesco ^b   Lauria, Francesco ^b   Ahmad, Humayun ^c   Kelly, Susan ^d   Liyanage, Anandika ^e   Ratnayake, Vijitha ^e   Shankari, Jagadeesan ^f   Whalley, Ioana ^g   Catovsky, Daniel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF SIENA   (Italy)

^c DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d BUCKINGHAMSHIRE HEALTHCARE NHS TRUST   (United Kingdom)

^e EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f BASILDON HOSPITAL   (United Kingdom)

^g IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

cladribine; Hairy cell leukemia; pentostatin; rituximab

Indexed keywords

CLADRIBINE; PENTOSTATIN; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; EOSINOPHILIA; FEMALE; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; PENTOSTATIN; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 79957474897     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.568650     Document Type: Article

References (12)

1. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007-3015. (Pubitemid 28417420)
2. Rafel M, Cervantes F, Beltrán JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000;88: 352-357. (Pubitemid 30051819)
3. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-896. (Pubitemid 46606450)
4. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003;17:45-51.
5. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476-1481. (Pubitemid 39264069)
6. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241-246. (Pubitemid 40967199)
7. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-740.
8. Zinzani PL, Pellegrini C, Stefoni V, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer 2010;116:4788-4792.
9. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658-4662. (Pubitemid 43882611)
10. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 2008;143:296-298.
11. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of relapsed/refractory hairy cell leukaemia. Cancer 2007;110: 2240-2247. (Pubitemid 350100746)
12. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53. (Pubitemid 40053062)